Fust Matthew K

CIK 00013972668 companiesEMERYVILLE, CA

SEC Profile

Transactions

Companies

Filings

CIK

0001397266

Recent Transactions

50 trades

Sale
Crinetics Pharmaceuticals, Inc.$CRNX
Common Stock
2025-09-26$44.75/sh−16,000→ 22,836 total
Exercise/Conversion
Crinetics Pharmaceuticals, Inc.$CRNX
Common Stock
2025-09-26$1.91/sh+10,000→ 38,836 total
Exercise/Conversion
Crinetics Pharmaceuticals, Inc.$CRNX
Stock Option (Right to Buy)
2025-09-26−10,000→ 2,092 total
Award
Crinetics Pharmaceuticals, Inc.$CRNX
Stock Option (right to buy)
2025-06-11+10,350→ 10,350 total
Award
Crinetics Pharmaceuticals, Inc.$CRNX
Common Stock
2025-06-11+6,900→ 28,836 total
Award
Atara Biotherapeutics, Inc.$ATRA
Common Stock
2025-06-10+7,828→ 18,188 total
Award
Neumora Therapeutics, Inc.$NMRA
Stock Option (Right to Buy)
2025-05-28+28,571→ 28,571 total
Award
Neumora Therapeutics, Inc.$NMRA
Stock Option (Right to Buy)
2025-05-28+85,586→ 85,586 total
Award
Neumora Therapeutics, Inc.$NMRA
Stock Option (Right to Buy)
2025-05-28+80,000→ 80,000 total
Disposition to Issuer
Neumora Therapeutics, Inc.$NMRA
Stock Option (Right to Buy)
2025-05-28−28,571→ 0 total
Disposition to Issuer
Neumora Therapeutics, Inc.$NMRA
Stock Option (Right to Buy)
2025-05-28−85,586→ 0 total
Award
Neumora Therapeutics, Inc.$NMRA
Stock Option (Right to Buy)
2025-05-28+27,802→ 27,802 total
Disposition to Issuer
Neumora Therapeutics, Inc.$NMRA
Stock Option (Right to Buy)
2025-05-28−27,802→ 0 total
Award
Ultragenyx Pharmaceutical Inc.$RARE
Common Stock
2025-05-15+5,740→ 25,945 total
Award
Ultragenyx Pharmaceutical Inc.$RARE
Stock Option (Right to Buy)
2025-05-15+10,787→ 10,787 total
Award
Neumora Therapeutics, Inc.$NMRA
Stock Option (Right to Buy)
2025-02-13+85,586→ 85,586 total
Disposition to Issuer
Neumora Therapeutics, Inc.$NMRA
Stock Option (Right to Buy)
2025-02-13−85,586→ 0 total
Award
Neumora Therapeutics, Inc.$NMRA
Stock Option (Right to Buy)
2025-02-13+28,571→ 28,571 total
Disposition to Issuer
Neumora Therapeutics, Inc.$NMRA
Stock Option (Right to Buy)
2025-02-13−28,571→ 0 total
Disposition to Issuer
Neumora Therapeutics, Inc.$NMRA
Stock Option (Right to Buy)
2025-02-13−27,802→ 0 total
Award
Neumora Therapeutics, Inc.$NMRA
Stock Option (Right to Buy)
2025-02-13+27,802→ 27,802 total
Exercise/Conversion
Neumora Therapeutics, Inc.$NMRA
Stock Option (Right to Buy)
2024-10-18−7,844→ 85,586 total
Exercise/Conversion
Neumora Therapeutics, Inc.$NMRA
Common Stock
2024-10-18$8.79/sh+6,205→ 26,305 total
Exercise/Conversion
Neumora Therapeutics, Inc.$NMRA
Stock Option (Right to Buy)
2024-10-18−6,205→ 0 total
Sale
Neumora Therapeutics, Inc.$NMRA
Common Stock
2024-10-18$17.03/sh−14,049→ 20,100 total
Exercise/Conversion
Neumora Therapeutics, Inc.$NMRA
Common Stock
2024-10-18$2.52/sh+7,844→ 34,149 total
Exercise/Conversion
Neumora Therapeutics, Inc.$NMRA
Stock Option (Right to Buy)
2024-10-17−2,156→ 93,430 total
Exercise/Conversion
Neumora Therapeutics, Inc.$NMRA
Stock Option (Right to Buy)
2024-10-17−1,800→ 6,205 total
Exercise/Conversion
Neumora Therapeutics, Inc.$NMRA
Common Stock
2024-10-17$8.79/sh+1,800→ 25,683 total
Exercise/Conversion
Neumora Therapeutics, Inc.$NMRA
Common Stock
2024-10-17$8.32/sh+3,783→ 23,883 total
Sale
Neumora Therapeutics, Inc.$NMRA
Common Stock
2024-10-17$17.01/sh−7,739→ 20,100 total
Exercise/Conversion
Neumora Therapeutics, Inc.$NMRA
Stock Option (Right to Buy)
2024-10-17−3,783→ 0 total
Exercise/Conversion
Neumora Therapeutics, Inc.$NMRA
Common Stock
2024-10-17$2.52/sh+2,156→ 27,839 total
Award
Ultragenyx Pharmaceutical Inc.$RARE
Common Stock
2024-06-18+5,345→ 20,205 total
Award
Ultragenyx Pharmaceutical Inc.$RARE
Stock Option (Right to Buy)
2024-06-18+9,900→ 9,900 total
Award
Neumora Therapeutics, Inc.$NMRA
Common Stock
2024-06-13+20,100→ 20,100 total
Award
Neumora Therapeutics, Inc.$NMRA
Stock Option (Right to Buy)
2024-06-13+28,571→ 28,571 total
Award
Crinetics Pharmaceuticals, Inc.$CRNX
Stock Option (right to buy)
2024-06-07+12,500→ 12,500 total
Award
Crinetics Pharmaceuticals, Inc.$CRNX
Common Stock
2024-06-07+3,400→ 21,936 total
Award
Atara Biotherapeutics, Inc.$ATRA
Common Stock
2024-03-31+150,000→ 259,000 total
Exercise/Conversion
Crinetics Pharmaceuticals, Inc.$CRNX
Stock Option (right to buy)
2024-03-20+17,500→ 0 total
Exercise/Conversion
Crinetics Pharmaceuticals, Inc.$CRNX
Stock Option (right to buy)
2024-03-20+17,500→ 0 total
Exercise/Conversion
Crinetics Pharmaceuticals, Inc.$CRNX
Stock Option (right to buy)
2024-03-20+12,500→ 0 total
Sale
Crinetics Pharmaceuticals, Inc.$CRNX
Common Stock
2024-03-20$45.50/sh−17,500→ 18,536 total
Sale
Crinetics Pharmaceuticals, Inc.$CRNX
Common Stock
2024-03-20$43.57/sh−12,500→ 18,536 total
Exercise/Conversion
Crinetics Pharmaceuticals, Inc.$CRNX
Common Stock
2024-03-20$23.24/sh+12,500→ 31,036 total
Exercise/Conversion
Crinetics Pharmaceuticals, Inc.$CRNX
Common Stock
2024-03-20$18.29/sh+17,500→ 36,036 total
Sale
Crinetics Pharmaceuticals, Inc.$CRNX
Common Stock
2024-03-20$43.58/sh−17,500→ 18,536 total
Exercise/Conversion
Crinetics Pharmaceuticals, Inc.$CRNX
Common Stock
2024-03-20$20.23/sh+17,500→ 36,036 total
Sale
Crinetics Pharmaceuticals, Inc.$CRNX
Common Stock
2024-03-20$43.57/sh−12,500→ 18,536 total

Companies

Recent Filings

Address

C/O ONYX PHARMACEUTICALS, INC. 2100 POWELL ST., 12TH FLOOR

EMERYVILLE, CA, 94608

View on SEC.gov